Syn-Ake
A small synthetic peptide designed to mimic waglerin-1 from Temple Pit Viper venom, marketed as blocking muscle acetylcholine receptors to soften expression lines. Often called 'topical Botox' — in the manufacturer's cell test it cut nerve-driven muscle-cell contractions by 82% at 2 hours, an effect that faded within days.
What is Syn-Ake?
Syn-Ake is a patented synthetic peptide — beta-alanyl-prolyl-diaminobutyric acid benzylamide, sold as its diacetate salt — designed to mimic the paralytic action of Waglerin-1, a 22-amino-acid peptide found in the venom of the Temple Pit Viper (Tropidolaemus wagleri). It acts as a reversible antagonist of the muscular nicotinic acetylcholine receptor (nmAChR), blocking the signal that tells facial muscles to contract. The result is a topical "Botox-like" muscle-relaxing effect that reduces dynamic wrinkles — the lines caused by repetitive facial expressions like frowning and squinting. In the manufacturer's test, human muscle cells were grown in a dish and overlaid with nerve tissue from a rat embryo so that they would twitch; 0.5 mM Syn-Ake cut how often they contracted by 82% after 2 hours, and the effect had largely worn off by day 4. Unlike Botox, which completely paralyzes muscles via injection, Syn-Ake works topically with a gentler, partial relaxation that softens wrinkles without freezing facial expression.
What Syn-Ake Is Investigated For
Syn-Ake is investigated as a topical cosmetic anti-wrinkle active that mimics the postsynaptic neuromuscular-junction pharmacology of waglerin-1 from Temple Pit Viper venom, with ancillary claims around MMP inhibition and antioxidant activity. The mechanistic evidence is in vitro: the manufacturer's 82% drop in contraction frequency of nerve-connected cultured muscle cells at 0.5 mM, alongside independent receptor testing showing that Syn-Ake blocks muscle-type acetylcholine receptors only at high micromolar concentrations — far weaker than waglerin-1 itself, which acts at nanomolar levels. Clinical efficacy data come almost entirely from the manufacturer: one peer-reviewed placebo-controlled study by DSM scientists (57 women aged 50 to 65, four weeks of a 4% formulation) found significantly less wrinkle area and length on the frowning forehead than placebo, and multi-ingredient serum trials report larger numbers that cannot be attributed to any single component. The honest caveats are substantial. Independent human data on Syn-Ake alone are limited to a five-person comparator arm in a study run by a rival peptide developer, waglerin-1 itself binds the mouse receptor about 100-fold more tightly than the rat or human versions, and whether the peptide actually reaches neuromuscular junctions in facial musculature at meaningful concentrations from topical application is the central unresolved question. The 'topical Botox' marketing framing overstates the effect size — botulinum toxin injection produces 50–80% dynamic wrinkle reduction within days, not comparable to topical Syn-Ake's softer, slower effect.
History & Discovery
Syn-Ake was developed by Pentapharm in Basel, Switzerland; its patent, filed with a November 2004 priority date by inventors Dominic Imfeld, Hugo Ziegler and Peter Wikstroem, claims H-(beta-Ala)-Pro-Dab-NH-benzyl among its preferred compounds. DSM acquired Pentapharm in 2007, and DSM merged with Firmenich in May 2023 to form dsm-firmenich. It was trademarked as a synthetic biomimetic of waglerin-1, a 22-amino-acid peptide isolated from the venom of the Temple Pit Viper (Tropidolaemus wagleri). Waglerin-1 acts as a competitive antagonist at the muscular nicotinic acetylcholine receptor (nmAChR), blocking acetylcholine binding at the postsynaptic neuromuscular junction — the venom mechanism behind paralysis and death by respiratory failure in mice. Mouse nerve-muscle studies show waglerin-1 also acts on the nerve side of the junction, so the venom is not a pure receptor blocker. Pentapharm's design distilled this venom pharmacology down to a much smaller synthetic molecule — three amino-acid building blocks (beta-alanine, proline and diaminobutyric acid) capped with a benzylamide and sold as the diacetate salt, about 496 daltons — which the patent says can be applied topically thanks to its relatively low molecular weight and suitable partition coefficient. The launch positioning was unmistakable: 'topical Botox' that worked at the muscle receptor instead of the nerve terminal, with the snake-venom story as a marketing centerpiece. Independent academic literature on the synthetic peptide is thin — most efficacy claims trace back to manufacturer-associated studies — and the regulatory and clinical framing has remained firmly within the cosmeceutical category rather than progressing toward drug-style evidence development.
How It Works
When you frown or squint, nerves release acetylcholine to tell facial muscles to contract. Over time, these repeated contractions create wrinkles. Syn-Ake blocks the receptor on the muscle side — like putting a lock on the door so the contraction signal can't get through. The muscles partially relax, and the wrinkles they create soften and smooth out.
Syn-Ake (dipeptide diaminobutyroyl benzylamide diacetate; H-beta-Ala-Pro-Dab-NH-benzyl as the diacetate, about 496 Da) is a small synthetic mimetic of Waglerin-1, a 22-amino-acid, disulfide-bonded peptide from Tropidolaemus wagleri venom. It is not waglerin-1 shortened; it is a much smaller molecule built to imitate its effect. The manufacturer describes it as a reversible antagonist of the muscle-type nicotinic acetylcholine receptor (nmAChR) that keeps the ion channel closed so the muscle cell does not depolarize. The epsilon-subunit selectivity often quoted for Syn-Ake is really a property of waglerin-1, which selectively blocks the adult, epsilon-containing mouse receptor; no published data show the small mimetic shares it, and one independent laboratory found Syn-Ake also inhibits the fetal, gamma-containing human receptor at high micromolar concentrations. In the manufacturer's innervated muscle-cell culture, 0.5 mM Syn-Ake reduced contraction frequency by 36% at 1 minute, 82% at 2 hours and 67% at 2 days, returning to near baseline by day 4 — the basis for calling the effect fully reversible. This postsynaptic mechanism is complementary to presynaptic approaches like Argireline (SNARE complex inhibition) and SNAP-8. A single computer-modelling study predicted binding to MMP-13 (strongest), MMP-8, and MMP-1 — never tested in enzyme or cell assays — which, if real, would suggest additional anti-aging activity through matrix metalloproteinase inhibition that would protect collagen and elastin from enzymatic degradation. The same study reported a predicted SIRT1 docking score of -9.32 kcal/mol and concentration-dependent DPPH radical scavenging in a test tube; neither has been demonstrated in skin cells or in people. A 2026 clinical study of a serum containing Syn-Ake plus Argireline showed 35-69% static wrinkle improvement and 10-13% dynamic wrinkle improvement over 12 weeks.
Evidence Snapshot
Human Clinical Evidence
Limited. The one peer-reviewed trial of Syn-Ake alone was written by DSM scientists: 57 women aged 50 to 65 applied a 4% formulation or placebo for four weeks, and the active group showed significantly less wrinkle area and length on the forehead when frowning (p < 0.05). A 2026 L'Oreal study of a five-active serum containing Syn-Ake, Argireline, gluconolactone, niacinamide and laminaria extract reported 35-69% static wrinkle improvement over 12 weeks and 10-13% dynamic wrinkle improvement in a second, smaller study (PMID: 41668671). However, multi-ingredient formulations make attribution to Syn-Ake specifically difficult.
Animal / Preclinical
Limited. No animal studies of Syn-Ake itself were found. In vitro: 82% lower contraction frequency at 0.5 mM after 2 hours in the manufacturer's innervated muscle-cell culture, and concentration-dependent inhibition of nicotine responses in a human cell line only at 250 to 500 micromolar (PMID: 39063099). Docking and simulation work predicted stable binding to MMP-13 and SIRT1 (PMID: 37349941); a cell-toxicity and bacterial-mutagenicity study in the same paper reported a safe laboratory dose range.
Mechanistic Rationale
Moderate. The nmAChR antagonism mechanism is well characterized for waglerin-1 itself, but the small mimetic is far weaker at the receptor and has not been shown to share waglerin-1's subunit or species selectivity. Its ability to replicate the activity topically through intact skin at cosmeceutical concentrations is the key question — in vitro receptor binding is demonstrated, but in vivo transdermal delivery efficiency is uncertain.
Research Gaps & Open Questions
What the current literature has not yet settled about Syn-Ake:
- 01Independent, non-industry-funded human trials on Syn-Ake specifically — the existing efficacy claims are dominated by Pentapharm/DSM-associated studies, and rigorous peer-reviewed independent replication of effect sizes is largely absent.
- 02Direct head-to-head comparisons with botulinum toxin (the implicit comparator in the marketing) and with other cosmetic neuromodulator peptides (Argireline, Vialox, Pentapeptide-18) at matched concentrations and durations.
- 03Real-world skin-penetration and target-site quantification across commercial formulations — whether the peptide actually reaches nmAChRs in facial musculature in clinically meaningful concentrations from topical application is the central unresolved question.
- 04Long-term human data — most published work spans 28-day to 12-week windows; multi-month and multi-year continuous use has not been studied as a distinct safety or efficacy question.
- 05Whether stacking Syn-Ake with similar postsynaptic peptides (Vialox) produces additive benefit or redundant target-site occupancy.
- 06Whether Syn-Ake shares waglerin-1's preference for the adult, epsilon-containing receptor and for mouse over human receptors — the only independent cell data show it also blocks the fetal, gamma-containing human receptor at high micromolar concentrations.
- 07Whether the predicted MMP and SIRT1 binding is real — it rests on a single docking and simulation study with no enzyme-activity, skin-cell, or human data.
- 08Translation of laboratory effect sizes (82% fewer contractions in cultured muscle cells at 0.5 mM) to outcomes in people, given that a 4% cream contains only about 0.01% peptide — the gap between mechanism strength and clinical effect size is large and informative.
Forms & Administration
Syn-Ake is used topically in cosmeceutical formulations — serums, creams, and eye treatments. Standard concentrations are 1-4% in finished products. Often combined with Argireline (presynaptic) and/or Matrixyl (collagen stimulation) for multi-target anti-aging. Applied to clean skin, typically twice daily. No prescription required for cosmeceutical products.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
The manufacturer recommends 1 to 4% of its Syn-Ake trade solution in a finished product. That solution contains 2,500 parts per million of the peptide, so a product labeled 4% Syn-Ake holds only about 0.01% actual peptide — the level used in the manufacturer's clinical studies. A 2025 survey of 245 snake-venom-themed cosmetics found labeled amounts ranging from 0.01% to 4%, and brands rarely state whether the figure refers to the trade solution or the pure peptide, so label percentages are hard to compare. No published human dose-response study exists.
Frequency
Applied topically once or twice daily to clean skin, targeting expression-line areas (forehead, glabella, crow's feet, perioral lines). Manufacturer studies typically used twice-daily application for 28 days before measuring wrinkle-depth endpoints; multi-peptide trials extend to 12 weeks.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Continuous indefinite use. Syn-Ake is a maintenance cosmetic active — the competitive, reversible nmAChR antagonism only operates while peptide is present at the receptor, so measurable benefit requires continued application. No cycling strategy is described in the cosmetic literature.
Protocol Notes
Skin penetration is the central practical caveat. The synthetic dipeptide derivative is smaller than the parent waglerin-1 venom peptide, which is a deliberate design choice for transdermal delivery, but it is still hydrophilic and faces the same stratum corneum barrier as other cosmetic peptides. The pharmacological target — nmAChRs at neuromuscular junctions in facial musculature — sits well below the epidermal layers that topical peptides typically reach, which is the fundamental gap between the laboratory result (82% fewer contractions of cultured, nerve-connected muscle cells at 0.5 mM) and modest wrinkle effects in people — and a 4% cream starts with only about 0.01% peptide to begin with. Syn-Ake is commonly stacked with Argireline (presynaptic SNARE-complex inhibition) on the rationale that hitting the neuromuscular junction from both pre- and postsynaptic sides should produce additive effects. It is also frequently combined with matrikine peptides (Matrixyl, Syn-Coll) for collagen support and with Vialox or Pentapeptide-18 in 'multi-target neuromodulator' product positioning. Head-to-head clinical evidence supporting stacking superiority over single-peptide products is limited. Waglerin-1 itself shows roughly 100-fold species selectivity favoring mouse over human nmAChR — an important note when interpreting how directly mouse or in vitro receptor data translates to human facial musculature.
Syn-Ake is a cosmetic ingredient, not a drug. It is not FDA-approved to treat or prevent any medical condition, and cosmetic claims permitted on labels are limited to appearance-related language. Do not inject cosmetic peptide products — there is no authorized injectable category for Syn-Ake and documented infection risk exists for unlicensed injection of cosmetic peptides.
Timeline of Effects
Onset
Manufacturer-sponsored studies typically begin to report measurable wrinkle-depth reduction at 14–28 days of twice-daily application. Immediate 'tightening' or smoothing sensations within minutes of application come from film-forming polymers and humectants in the vehicle, not from real-time receptor blockade.
Peak Effect
Studies of Syn-Ake alone stop at 28 days, so a true peak has never been measured. Multi-peptide trials combining Syn-Ake with Argireline report 35–69% improvement in static wrinkle measures and a more modest 10–13% improvement in dynamic wrinkle measures over 12 weeks — though attribution to Syn-Ake specifically is difficult in multi-ingredient formulations. For comparison, a single botulinum toxin treatment makes the large majority of patients responders within about a month in pivotal trials; topical Syn-Ake effects, where present, are far softer in magnitude and develop over weeks.
After Discontinuation
No study has followed people after they stop using Syn-Ake, so the offset timeline is unknown. In the manufacturer's cell test, the contraction-blocking effect of a single dose had largely worn off within four days, consistent with a reversible action that requires continued use. There is no described withdrawal or rebound pattern.
Common Questions
How does Syn-Ake compare to Botox?
Different mechanism, different delivery, different intensity. Botox (botulinum toxin) is injected and blocks acetylcholine release from nerve endings — complete paralysis at the injection site. Syn-Ake is applied topically and blocks acetylcholine reception at the muscle — partial relaxation without immobilization. Botox is far more potent but requires medical administration. Syn-Ake is gentler and available over the counter in skincare products.
How does Syn-Ake compare to Argireline (acetyl hexapeptide-8)?
Both reduce wrinkles by limiting muscle contraction, but at different points. Argireline inhibits SNARE complex formation, blocking neurotransmitter release (presynaptic). Syn-Ake blocks the acetylcholine receptor on the muscle itself (postsynaptic). They are often combined on the theory that hitting both sides of the neuromuscular junction adds up, but no study has isolated a synergistic effect.
Is Syn-Ake the same as Tripeptide-3?
Not officially. Many reviews call Syn-Ake 'Tripeptide-3', and the manufacturer describes it as a tripeptide because it is built from three amino-acid units — beta-alanine, proline and diaminobutyric acid — capped with a benzylamide. But its registered ingredient name is dipeptide diaminobutyroyl benzylamide diacetate, and Tripeptide-3 is a separate entry in the EU ingredient database, defined as a peptide of glycine, serine and valine. On a label, look for the registered name.
How much peptide is really in a 4% Syn-Ake cream?
Very little. The percentage almost always refers to the manufacturer's trade solution, which carries the peptide at 2,500 parts per million. A cream made with 4% of that solution contains about 100 parts per million — roughly 0.01% — of the actual peptide, which is the level used in the manufacturer's own clinical studies. That is well below the 0.5 millimolar concentration used in the laboratory cell test, before accounting for anything lost at the skin barrier.
What does the '82% fewer muscle contractions' figure actually measure?
It comes from the manufacturer's laboratory test, in which human muscle cells were grown in a dish and overlaid with nerve tissue from a rat embryo so that they would twitch. Adding Syn-Ake at 0.5 millimolar cut how often they contracted by 36% after one minute and 82% after two hours; by two days the reduction was 67%, and by day four contractions were back near normal. It is a measurement of twitch frequency in a dish, not a wrinkle result — the human studies report improvements in the range of roughly 15 to 20% over four weeks.
Is there any independent evidence Syn-Ake works?
Very little, and most of it comes from companies developing rival peptides. A Korean cosmetics laboratory used Syn-Ake as a comparator in a 2026 split-face pilot with five people per arm and reported modest reductions in crow's-feet depth and volume after four weeks. Receptor testing published by another company found that Syn-Ake blocks muscle acetylcholine receptors only at high micromolar concentrations. A 2020 academic review of cosmeceutical peptides noted that it had found no scientific papers describing clinical studies of the peptide at all — the main manufacturer trial was published the same year.
Does Syn-Ake actually contain snake venom?
No. Syn-Ake is a fully synthetic three-residue peptide made in a lab. It was designed to mimic the receptor-blocking action of Waglerin-1 from viper venom, but contains no animal-derived ingredients. The 'snake venom' marketing is based on the biomimetic inspiration, not the source material.
How long does it take to see results from Syn-Ake?
Manufacturer studies generally measure wrinkle-depth changes at 14-28 days of twice-daily application, with peak effects around 28 days at 4% concentration. Multi-peptide trials extend to 12 weeks. Any immediate 'tightening' people notice within minutes of application is from film-forming polymers and humectants in the vehicle — not from real-time receptor blockade. Plan on 4-8 weeks of consistent use before judging whether a given Syn-Ake product is working for you, and expect a softer, slower effect than injectable neuromodulators.
Can Syn-Ake actually penetrate skin deep enough to reach facial muscles?
This is the central unresolved question and the most honest critique of the category. Syn-Ake targets nicotinic acetylcholine receptors at neuromuscular junctions, which sit well below the epidermal layers that topical peptides typically reach. The synthetic dipeptide is deliberately smaller than the parent waglerin-1 venom peptide to help with transdermal delivery, but stratum corneum permeation is still the rate-limiting step. In vitro receptor binding is well-demonstrated at the bench; how much peptide actually reaches the target site in human facial musculature from a topical cream is poorly quantified. The modest size of clinically observed wrinkle-depth changes — compared with the dramatic in vitro contraction reduction — suggests delivery is partial at best.
Who Syn-Ake Is NOT For
- •Broken, irritated, or actively inflamed skin — wait until the skin barrier is intact before applying cosmetic peptide serums; application to compromised skin increases irritation potential and any systemic absorption.
- •Known hypersensitivity to Syn-Ake or to other components of the cosmetic vehicle (preservatives, fragrances, emulsifiers); no Syn-Ake-specific contact dermatitis case reports turned up in a PubMed search, though reactions to other ingredients in the vehicle are possible.
- •Pregnancy and breastfeeding — topical cosmetic use on intact skin is generally considered low-risk, but there is no dedicated safety data in pregnancy, and the receptor-targeting mechanism makes a conservative default to minimize use during this window reasonable.
- •Pediatric use — no data and no clinical reason for children or adolescents to use anti-wrinkle peptides.
- •Do not inject cosmetic Syn-Ake preparations — these are not sterile injectable products, not manufactured under injectable standards, and there is no clinical basis for injection.
- •Patients with pre-existing neuromuscular disorders (myasthenia gravis, Lambert-Eaton syndrome) should consult a clinician before using nmAChR-targeting cosmetic peptides, even though systemic exposure from topical use is expected to be negligible.
Drug & Supplement Interactions
Documented pharmacological drug interactions for topical Syn-Ake are minimal. Systemic absorption from typical topical use is low enough that meaningful interaction with oral or injected medications is not expected. The practical interaction space is topical layering with other actives. Syn-Ake is compatible with most cosmetic ingredients — niacinamide, hyaluronic acid, ceramides, and other peptides layer readily. Co-formulation with Argireline is common and marketed as synergistic on the rationale that pre- and postsynaptic mechanisms hit different points in the same neuromuscular cascade. Stacking with Vialox (which targets a similar postsynaptic receptor) is common but raises a redundancy question — if both peptides compete for the same nmAChR site, additive benefit is theoretically capped. Layering with matrikine peptides (Matrixyl, Syn-Coll) combines independent mechanisms. High-concentration L-ascorbic acid (vitamin C) is acidic enough that concurrent same-layer application can destabilize peptide actives and is typically used at a different time of day. Strong AHA/BHA exfoliation on the same evening as Syn-Ake can reduce peptide activity at the surface and increase irritation, so spacing is sensible. There is no documented concern with oral medications, systemic hormones, or anticoagulants at the level of topical cosmetic exposure. There is no evidence that Syn-Ake interferes with botulinum toxin. A small uncontrolled 2026 study applied a multi-peptide cream containing Syn-Ake and Argireline after botulinum toxin treatment and reported a longer interval before reinjection, but without a control group it cannot show the peptides caused the change.
Safety Profile
Common Side Effects
Cautions
- • Not FDA-approved as a drug — marketed as a cosmeceutical ingredient
- • Topical efficacy is limited by skin penetration — not as potent as injectable muscle relaxants
- • Clinical studies often use multi-ingredient formulations, making it hard to isolate Syn-Ake's specific contribution
- • Over-the-counter products vary widely in concentration and formulation quality
What We Don't Know
Long-term effects of chronic topical nmAChR antagonism on facial muscles are not studied. Whether meaningful receptor blockade occurs through intact skin at cosmeceutical concentrations is debated. Most clinical data comes from manufacturer-sponsored studies (DSM/Pentapharm). Independent clinical replication is limited.
Legal Status
United States
Regulated as a cosmetic ingredient under FDA cosmetic law, not as a drug. Over-the-counter sale in finished cosmetic formulations is permitted without prescription. Syn-Ake (dipeptide diaminobutyroyl benzylamide diacetate) is INCI-listed and appears in many over-the-counter anti-wrinkle products. Not approved as a drug for wrinkles or any other medical indication — labels are limited to cosmetic appearance claims. The 'snake venom' marketing language describes biomimetic design inspiration, not source material; the ingredient is fully synthetic.
International
Listed in the EU CosIng cosmetic-ingredient inventory as dipeptide diaminobutyroyl benzylamide diacetate, a skin-conditioning agent, and sold in cosmetics worldwide. No formal US or EU expert safety opinion specific to it was found. In a 2025 survey of 245 snake-venom-themed cosmetics, most came from European brands, with South Korea the largest Asian source.
Sports & Competition
Not listed on the WADA Prohibited List and not a realistic doping concern. Topical cosmetic peptides have negligible systemic exposure relevant to performance.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Syn-Ake is synthetic waglerin-1.
Reality
No. Waglerin-1 is a 22-amino-acid venom peptide held in shape by a disulfide bond. Syn-Ake is a far smaller molecule: three amino-acid units, two of them non-standard, plus a benzylamide cap, at about 496 daltons. It was designed to imitate waglerin-1's receptor-blocking effect, and in receptor testing it is orders of magnitude weaker — micromolar rather than nanomolar. The alias 'synthetic waglerin-1' overstates the relationship.
Myth
Syn-Ake is 'topical Botox' and produces comparable results to injection.
Reality
The marketing framing is misleading. Syn-Ake reversibly blocks the muscle nicotinic acetylcholine receptor; botulinum toxin enzymatically cleaves SNARE proteins inside nerve terminals to abolish acetylcholine release entirely. Botulinum toxin produces 50–80% wrinkle reduction within days; topical Syn-Ake, when effective, produces softer reductions over weeks. The mechanisms are different, the magnitudes are different, and Syn-Ake does not substitute for injection.
Myth
Syn-Ake contains real snake venom.
Reality
Syn-Ake is a fully synthetic dipeptide derivative manufactured in a lab. It was designed to mimic the receptor-blocking activity of waglerin-1 from Temple Pit Viper venom, but contains no animal-derived material and no actual venom. The 'snake venom peptide' marketing describes biomimetic design inspiration, not source.
Myth
Higher concentrations of Syn-Ake produce proportionally better wrinkle reduction.
Reality
Stratum corneum permeation is the rate-limiting step, not vehicle concentration. Above the manufacturer's tested 4% range, additional peptide in the serum mainly increases label appeal. Vehicle and formulation choices (encapsulation, penetration enhancers, occlusion) drive delivered dose more than nominal label percentage.
Myth
Syn-Ake can be safely injected for a stronger effect.
Reality
Cosmetic Syn-Ake preparations are not sterile injectable products, not manufactured under injectable standards, and there is no authorized injectable category. Injecting cosmetic peptide products carries documented infection risk — a 2021 case report describes Mycobacterium abscessus abscesses in a woman after Argireline was injected into her forehead and temples.
Myth
Stacking Syn-Ake with Vialox and Argireline triples the wrinkle-reduction effect.
Reality
Syn-Ake and Vialox both target the postsynaptic nmAChR — stacking them likely produces redundant occupancy of the same target rather than additive benefit. Combining a postsynaptic receptor blocker with a presynaptic SNARE inhibitor (Argireline) is mechanistically more complementary, but clinical evidence that multi-peptide stacks meaningfully outperform a single well-formulated cosmetic peptide is limited.
Published Research
12 studiesIn Vitro and Clinical Evaluation of the Anti-Wrinkle Efficacy of Medipep-6PN, a Novel Peptide Identified by Phage Display.
The effect of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone on skin biomarkers, wrinkles and skin texture: Ex vivo and clinical studies.
Wrinkle-Improving Effect of Novel Peptide That Binds to Nicotinic Acetylcholine Receptor.
Anti-aging activity of Syn-Ake peptide by in silico approaches and in vitro tests.
What Are the Neurotoxins in Hemotoxic Snake Venoms?
Mycobacterium abscessus infection after facial injection of argireline: A case report.
Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy.
Viper Venom Botox: The Molecular Origin and Evolution of the Waglerin Peptides Used in Anti-Wrinkle Skin Cream.
Identification of residues at the alpha and epsilon subunit interfaces mediating species selectivity of Waglerin-1 for nicotinic acetylcholine receptors.
Waglerin-1 selectively blocks the epsilon form of the muscle nicotinic acetylcholine receptor.
Establishes the selectivity that Syn-Ake marketing borrows: waglerin-1 blocks the adult, epsilon-containing mouse muscle receptor at nanomolar concentrations. The much smaller synthetic mimetic has never been shown to share this property.
Facial Expression Wrinkles and Their Relaxation by a Synthetic Peptide
The only peer-reviewed placebo-controlled trial of Syn-Ake on its own, authored by DSM scientists. 57 women aged 50 to 65 applied a 4% formulation or placebo for four weeks; the active group showed significantly less wrinkle area and length on the forehead when frowning (p < 0.05).
Viper Venom and Synthetic Peptides: Emerging Active Ingredients in Anti-Ageing Cosmeceuticals.
Quick Facts
- Class
- Cosmeceutical Peptide
- Tier
- D
- Evidence
- Preliminary
- Safety
- Moderate Data
- Updated
- Sep 2026
- Citations
- 12PubMed
Also known as
Tags
Peptide Families
Related Goals
Conditions Discussed
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.